Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM. Gottlieb RL, et al. Among authors: skovronsky dm. JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202. JAMA. 2021. PMID: 33475701 Free PMC article. Clinical Trial.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM; BLAZE-1 Investigators. Chen P, et al. Among authors: skovronsky dm. N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28. N Engl J Med. 2021. PMID: 33113295 Free PMC article. Clinical Trial.
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, Stemer A, Mayer SM, Wohl D, Brengle B, Montague BT, Frank I, McCulloh RJ, Fichtenbaum CJ, Lipson B, Gabra N, Ramirez JA, Thai C, Chege W, Gomez Lorenzo MM, Sista N, Farrior J, Clement ME, Brown ER, Custer KL, Van Naarden J, Adams AC, Schade AE, Dabora MC, Knorr J, Price KL, Sabo J, Tuttle JL, Klekotka P, Shen L, Skovronsky DM; BLAZE-2 Investigators. Cohen MS, et al. Among authors: skovronsky dm. JAMA. 2021 Jul 6;326(1):46-55. doi: 10.1001/jama.2021.8828. JAMA. 2021. PMID: 34081073 Free PMC article. Clinical Trial.
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM; BLAZE-1 Investigators. Dougan M, et al. Among authors: skovronsky dm. N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14. N Engl J Med. 2021. PMID: 34260849 Free PMC article. Clinical Trial.
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Dougan M, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Blomkalns A, Adams AC, Van Naarden J, Custer KL, Knorr J, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Sabo J, Patel DR, Dabora MC, Williams M, Klekotka P, Shen L, Skovronsky DM, Nirula A. Dougan M, et al. Among authors: skovronsky dm. Clin Infect Dis. 2022 Aug 24;75(1):e440-e449. doi: 10.1093/cid/ciab912. Clin Infect Dis. 2022. PMID: 34718468 Free PMC article. Clinical Trial.
Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.
Nirula A, Shen L, Skovronsky DM. Nirula A, et al. Among authors: skovronsky dm. N Engl J Med. 2021 Jan 14;384(2):189. doi: 10.1056/NEJMc2033787. Epub 2020 Dec 30. N Engl J Med. 2021. PMID: 33378611 No abstract available.
Donanemab in Early Alzheimer's Disease.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Mintun MA, et al. Among authors: skovronsky dm. N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. N Engl J Med. 2021. PMID: 33720637 Clinical Trial.
Use of florbetapir-PET for imaging beta-amyloid pathology.
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group. Clark CM, et al. Among authors: skovronsky dm. JAMA. 2011 Jan 19;305(3):275-83. doi: 10.1001/jama.2010.2008. JAMA. 2011. PMID: 21245183 Free PMC article.
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group; AV45-A11 Study Group. Doraiswamy PM, et al. Among authors: skovronsky dm. Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11. Mol Psychiatry. 2014. PMID: 24614494 Free PMC article.
75 results